Public Health Agency of Canda in collaboration with U.S. pharmaceutical company BioProtection System, a unit of Newlink Genetics, have discovered an Ebola vaccine tested in monkeys with good results, as affirmed by Profectus BioSciences chief science officer John Eldridge. The U.S. and Canadian joint-venture Ebola vaccine has been discovered one years ago, and now is almost ready to be licensed for commercialization to U.S. and Canada markets. The only obstacle for its commercialization is the absence of test in humans an obligatory step forecast by World Health Organization to commercialize all new vaccine and treatments.
This problem has been resolved with humanitarian donation that will permit to start Canadian Ebola vaccine human tests. The first human “voluntaries” will be Africans thanks to a donation of 1,000 doses of experimental vaccine done by Canadian Government to World Health Organization to start large experimentation on human in African countries affected by Ebola under U.S. Department of Defense monitoring in line with the contract signed with Canadian Government.
The new Ebola vaccine worldwide commercialization will depend to the result of clinical trials on Africans, Canadian Health Minister Rona Ambrose and Dr. Margaret Chan, WHO General Director said. “Canadian Ebola vaccine have been tested in monkeys with good results. Unlucky the experimentation on human is very difficult because of the rigid legislations of several countries. We really don’t know how safe it is or witch side effects are going to be. But in this extraordinary circumstance in Africa right now, we will trying to do everything we can to fight Ebola outbreak” chief science officer John Eldridge said to Reuters Africa. If the result will be positive there will need four to six months to make a large quantity in order to commercialize worldwide Canadian vaccine that is separate from the treatment called ZMapp.
This experimental Ebola treatment is being developed by Canada’s Tekmira Pharmaceuticals Corporation in collaboration with U.S. firm Mapp Biopharmaceutical that has been used to treat to infected American aid workers with not yet clear results. ZMapp treatment will be experimented in Africa too Dr. Greg Taylor, Public Health Agency of Canada deputy chief told Reuters in an interview ahead of the Canadian announcement. Liberia government has declared to be ready to authorize both experimentations over its citizens affected by Ebola. Liberia is one of more West Africa countries affected of Ebola outbreak.
One week ago Liberian Army has set up road blocks to limit travel from Grand Cape Mount province (one of the worst affected areas in the country) to the capital Monrovia. Similar military health cordons have set up in Sierra Leone where 800 troops have been sent to guard hospital treating Ebola patients in order to assure the epidemic containment. In Nigeria have been registered some isolate Ebola cases meantime in DR Congo and Uganda (other two continental Ebola strongholds) there are no Ebola cases reported. In West Countries has been registered the phenomenon of withdraw of Ebola patients receiving treatment in the hospital done by their family that don’t trust the national health system. This may be the cause of military health cordons in Liberia and Sierra Leone. According to WHO data of Thursday August 14 Ebola claimed al least 1.004 lives and infected nearly 2.000 people since breaking out in Guinea earlier this year.
These humanitarian donations will resolve the human test license very complicated to obtain in developed countries and will protect Canadian and U.S. pharmaceutical corporations from eventual legal issue in case of failures and the death of human patients. US health regulations will lose their restriction power over experimental drug thanks to these humanitarian donations alloying to try vaccine and treatment on infected patients in Africa. This confirm the suspects of several scientists and human rights activists that Western Medias have create a false Ebola global outbreak risk in order to permit illegal human experimentation.
In case of positive results vaccine and treatments will be commercialized forcing Governments of developed countries to buy huge quantity to fight a global outbreak that has heavy possibilities to never happen. African population will have the possibility to access to vaccine and treatments only if African Government will be able to provide necessary funds or U.N. Humanitarian Agency and WHO will take in charge the costs, despite that Africa will offer humans to test the new pharmaceutical discoveries and are the unique victims of Ebola pandemic at the moment.
Legal and ethical issues linked to drug experimentation in human have been resolved by WHO public affirmation that it is ethical and right to offer untested drugs and vaccine to people infected by the virus as reported by Reuters Africa. This decision will open the door for easy and unmonitored human tests in Africa. A reality till now semi clandestine in many Africans countries concerning HIV/AIDS and other sickness treatment and vaccine researches. This convenient but unusually procedure will have the risk that international human experimentation standard procedures will not be respected. The standard procedures force all new medicine and vaccines to a serial of trial in human realized in small scale in order to avoid mass death of patients in case of failure. In this case almost 2,000 patients are already available for experimentation. This number of patients will destroy the international obligation of limited experimentation on human.
Humanitarian donation of vaccine and treatment will break the juridical obligation of the voluntary patients internationally recognized. Every patients on new drug experimentation must be voluntary and in full knowledge of mortal risk in case of failure of laboratory experimentations. In this case African patients, already sick, will have no many choices: Die or become guinea pigs for Canadian and US pharmaceuticals corporation with the hope that the new drugs will work. Most probably the international right of risks knowledge will be ignored offering drugs and vaccine to ill patients semi illiterate that are desperately fight to survive. Pharmaceutical Corporations will avoid legal consequences and the obligation to offer health assistance to patients in case of failure of the experimentation, too.
In order to stop these unethical experimentations African countries shall have the courage to fights against WHO indications and create a strong legislation on merit. This will be possible in emerging African countries like Angola, Mozambique, Ghana, Kenya, Ethiopia, Nigeria, Rwanda, South Africa, Tanzania, Uganda. The others countries will have less capacity to stop unethical experimentation meanly the poor African countries affected from Ebola outbreaks from July 2014 to date like: Liberia, Sierra Leone and Guinea.